Wed., Feb 26, /2019 – 1:00PM — OCEAN TOMO
Ocean Tomo Transactions has been retained to conduct a private auction for the global patent portfolio and trademark assets related to absorbable surgical adhesives and sealants owned by Cohera Medical Inc.(R).
SAN FRANCISCO (PRWEB) FEBRUARY 06, 2019
Ocean Tomo Transactions has been retained by DSI Assignments, LLC, the Assignee of Cohera pursuant to an Assignment for the Benefit of Creditors, to conduct a private auction of the Cohera Medical Inc® absorbable surgical adhesives and sealants global patents, open applications and trademarks. The sale is by order the Chancery Court for the State of Delaware.
Subject to any approval that may be required by the Chancery Court for the State of Delaware in connection with the Assignment for the Benefit of Creditors of Cohera®, the highest bid as of February 25, 2019 (Midnight, PST) in the private auction, will acquire the intellectual property assets for the formulation, delivery device and methods covered by the Cohera surgical adhesive and sealants intellectual property.
Marketed by Cohera under the trade name TissuGlu®, the practice of the art disclosed in the patents resulted in the first 100% synthetic internal surgical adhesive approved for sale in the United States. TissuGlu, designed to meet a surgeon’s need for a strong, biocompatible and easy-to-use surgical adhesive, is an alternative to the use of postoperative fluid collection drains in mastectomy surgeries. It was also approved in the US for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in abdominoplasty; TissuGlu passed all bio-compatibility testing as a Class III permanent implant.
With the market for surgical drains projected to rise from it’s estimated 2018 value of $1.90 billion USD to an estimated value of $2.64 billion USD by 2026, the acquirer of this portfolio of issued patents, pending applications and trademarks will have intellectual property assets with both early priority dates and important open applications in the areas of hydrophilic adhesives, pressure sensitive adhesives, spray and drop dispenser technologies.
In March of 2018, Cohera submitted a Premarket Approval Application (PMA) supplement to the U.S. Food and Drug Administration (FDA) for TissuGlu Surgical Adhesive providing new clinical evidence supporting a review by the FDA to expand the indication for TissuGlu in the US for mastectomy, pressure ulcer and other breast procedures with a combined addressable market exceeding $1 billion USD.
CONTACT FOR OCEAN TOMO:
Kristi L. Stathis
Chief Marketing Officer
Ocean Tomo, LLC
+1 773 294 4360